| 1(888)341-2393 | (301) 608-0370

ISO 21702 – Measurement of antiviral activity on plastics and other non-porous surfaces


Purpose and Goals

  • Evaluate and compare the antiviral activity of non-porous materials against various viruses in laboratory-controlled testing. 


  • Sections (50 mm x 50 mm or 1” x 3”) of the test material will be disinfected with an ethanol solution, inoculated with a liquid viral suspension, and covered with a sterile inert film to maximize the contact area (40 mm x 40 mm or equivalent). The inoculated sections will be incubated for the specified time-point in a humidified chamber. After contact, the remaining virus from each section will be recovered into a neutralizing solution and then dilution-plated on host cultures to provide quantifiable active viral burden data for each section tested.
  • Each test will include one of the viral strains:
    • Human Coronavirus strain OC43 (HCoV-OC43) (ATCC VR-1558), an enveloped RNA betacoronavirus like the recent pandemic strain SARS-CoV-2.
    • Human Coronavirus strain 229E (HCoV-229E) (ATCC VR-740), an enveloped RNA alphacoronavirus.
    • Human Coronavirus strain NL63 (HCoV-NL63) (NIAID-BR NR-470), an enveloped RNA alphacoronavirus.
    • Influenzavirus A (H1N1) (ATCC VR-1469), an enveloped RNA virus.
    • Influenzavirus A (H3N2) (ATCC VR-1680), an enveloped RNA virus.
    • Feline Calicivirus (FCV) strain F-9 (ATCC VR-782), a small non-enveloped RNA virus, the laboratory surrogate for human norovirus. 
  • Testing will include 12 total data points per viral strain:
    • 2 materials: such as 1 test material and 1 in-house negative control.
      • Note: Please provide at least 15,000 cm2 of each material per time-point. 
      • A sterile glass slide will be used as the negative control surface. 
  • 2 time-points: 0 and 24 hours.
  • 2 replicates sections of each test material at each test condition
  • Note: Optional GLP services are available for an additional fee.

Data Analysis

  • In-house control results will be used to verify test validity. 
  • Data will be calculated to determine the quantifiable viral burden in plaque- or foci-forming units per square centimeter of contact area (PFU/cm2 or FFU/cm2) remaining on each sample.
  • Data will be analyzed to determine the consistency between replicate samples in each set (n=2).
  • Data will be analyzed to determine the percent reductions and log reductions of viral burdens on each test material compared to the negative control at each test condition.